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Abstract
The molecular basis of how chromosome 16p13.11 microduplication leads to major psychiatric disorders is unknown. Here
we have undertaken brain imaging of patients carrying microduplications in chromosome 16p13.11 and unaffected family
controls, in parallel with iPS cell-derived cerebral organoid studies of the same patients. Patient MRI revealed reduced
cortical volume, and corresponding iPSC studies showed neural precursor cell (NPC) proliferation abnormalities and
reduced organoid size, with the NPCs therein displaying altered planes of cell division. Transcriptomic analyses of NPCs
uncovered a deficit in the NFκB p65 pathway, confirmed by proteomics. Moreover, both pharmacological and genetic
correction of this deficit rescued the proliferation abnormality. Thus, chromosome 16p13.11 microduplication disturbs the
normal programme of NPC proliferation to reduce cortical thickness due to a correctable deficit in the NFκB signalling
pathway. This is the first study demonstrating a biologically relevant, potentially ameliorable, signalling pathway underlying
chromosome 16p13.11 microduplication syndrome in patient-derived neuronal precursor cells.
Introduction
Species-specific evolutionary expansion of cortical structure
and circuitry underlies the unique range of human cognitive
abilities. Whilst rodent models of brain development and
function are invaluable, inherent differences in the
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organisation and structure of the human neocortex requires
complementary human experimental systems to model
aspects of neurodevelopmental disorders such as schizo-
phrenia (SCZ) and autism spectrum disorders (ASDs).
Human induced-pluripotent stem cell (iPSC) technology,
coupled to genetic discoveries, and the ability to reconstruct
3D cortical structures offers an unprecedented opportunity
to better understand the mechanisms underlying major
psychiatric disorders.
Copy number variations (CNVs), such as those found at
chromosome 16p13.11 locus are associated with a range of
phenotypically different neurodevelopmental disorders
including SCZ [1–4], intellectual disability [5, 6] and ASD
[5], which suggest that the locus contains dosage-sensitive
gene(s) with a critical role in neurodevelopment. The
deCODE genetics study of 4345 patients with SCZ and
35,079 controls from eight European populations found a
threefold excess of duplications and deletions at the 16p13.1
locus in SCZ cases, with duplications being far more
commonly found [3]. Mirroring this, in a Scottish popula-
tion sample we found a fourfold excess of duplications at
the 16p13.1 locus in SCZ patients compared to controls [7].
Despite this, the molecular basis of how 16p13.11
microduplication leads to major psychiatric disorders is
unknown. Ingason et al. [3] subdivided the 16p13.11
region, between 14.66 and 18.70Mb, into three single-copy
sequence intervals, denoted intervals I, II and III, each of
which is flanked by sequences rich in low copy repeats
(LCR). All duplications and deletions so far reported are
contained within this region with the most common
breakpoints in the LCR clusters distal to interval I and
proximal to interval II (so called Dup I+ II carriers) [3].
Given that Dup I+ II carriers showed the highest common
odds ratio of all 16p13.11 microduplication carriers, we
decided to focus on familial carriers of this CNV. The core
genetic locus, conserved across mice and humans, contains
seven genes and it has long been proposed that a key gene
in this region is NDE1 (Nuclear Distribution protein nudE
homolog 1 also known as nude neurodevelopmental pro-
tein) with deletions and duplications spanning NDE1
amongst the most common CNVs in SCZ [3]. However, a
recently described bacterial artificial chromosome-
transgenic mouse model, carrying a human 16p13.11
locus, has been shown to exhibit a behavioural hyper-
activity phenotype associated with miR-484 overexpression
with resultant decreased proliferation and increased differ-
entiation of neural progenitors in vivo [8] calling into
question whether the key gene is NDE1 or another gene in
the locus such as miR-484 or indeed a combination of these
genes that is responsible for the phenotypes associated with
the 16p13.11 microduplication.
Over the years the evidence for NDE1 has mounted from
rodent studies: NDE1 encodes a cytoskeletal protein that is
part of the LIS1/cytoplasmic dynein complex localising to
the centrosome [9–11] where it participates in a range of
essential neurodevelopmental processes including NPC
proliferation, neuronal migration, intracellular transport and
neurite outgrowth [12–14]. NDE1 and its paralogue NDEL1
(Nuclear distribution protein nudE-like 1) form an epistatic
interaction where NDE1 and NDEL1 compete with one
another for binding to the SCZ risk factor DISC1 [15] with
mutations in both NDE1 and NDEL1 resulting in defective
neurogenesis and neuronal migration [16–19]. Recently, it
has been shown that DISC1 regulates neurogenesis via
modulating kinetochore attachment of NDEL1/NDE1 dur-
ing mitosis, demonstrating a critical role of the DISC1/
NDEL1 interaction in regulating mitosis of radial glial
progenitors (RGPs), both in the developing mouse cortex
in vivo and in human forebrain organoids from an individual
with schizophrenia who carries a 4-bp deletion of DISC1
[20]. This mutation results in the production of truncated
DISC1, abolishing its interaction with NDEL1. Further-
more, it has been shown that familial mutations in NDE1
can cause both severe failure of neurogenesis and a defi-
ciency of cortical lamination [21, 22].
Rare single-nucleotide polymorphisms (SNPs) in NDE1
also associate with SCZ and psychosis susceptibility
[23, 24], with the latter conditioned on a DISC1 associating
risk haplotype [24]. Taken together, the genetic and biolo-
gical evidence for DISC1 and NDE1 suggest a shared ‘risk’
pathway in neurodevelopmental disorders although the
precise mechanism(s) of action has remained elusive.
Recently, Bradshaw et al. [25], using gene expression and
psychoactive medication data, have elegantly demonstrated
that the NDE1 SNP rs2242549 associates with significant
changes in gene expression and that a significant number of
these were predicted targets of miR-484, located within a
non-coding exon of NDE1. This has led to the hypothesis
that variation at the NDE1 locus may alter risk of mental
illness, in part through modification of miR-484, high-
lighting this as a potentially important locus in targeting
treatment [25].
We hypothesized that genetic interactions, within the
biological network linked to specific genes within 16p13.11
dup, would rise to the level of clinical association and that
patient-derived iPSC studies could provide an important
opportunity to identify these pathways. Structural brain
imaging of carriers compared to unaffected family controls
revealed reduced cortical volumes that was mirrored by
smaller cerebral organoids in vitro. Furthermore, we show
reduced ventricular zone and NPC proliferation associated
with deficits in the NFκB p65 pathway that upon pharma-
cological or genetic activation corrects the proliferation
deficit. This study integrates patient and cellular studies to
demonstrate a role for genes within the 16p13.11 locus (in
particular NDE1) in human corticogenesis, and implicates
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dysregulation of NFκB as an important potential mechan-
istic pathway in neurodevelopmental and neuropsychiatric
disorders.
Materials and methods
Patient recruitment and assessment
Patient diagnosis was carried out, according to ICD-10 and
DSM-IV-TR criteria. The study was approved by the
Multicentre Research Ethics Committee for Scotland (REC
reference: 13/SS/0039; IRAS project ID: 147086). A
detailed description of the study was given and written
informed consent was obtained from all individuals prior to
participation. A summary of the individual participants,
their diagnosis, CNV status, medications at the time of
study, and their age at onset, biopsy and MRI is shown in
Supplementary Table 1 and detailed in supplementary
methods.
Structural MRI data acquisition
All brain images were acquired on a Siemens Skyra 3.0T
scanner (Siemens Medical Solutions, Germany) (see sup-
plementary materials). As NDE1 is hypothesised to have an
important role in neuronal proliferation, migration and
corticogenesis, we focused structural imaging analysis on
measures of cortical thickness (CT). FreeSurfer software
(v5.3) [26] was used to derive measures of global and lobar
cortical thickness (frontal, temporal, parietal and occipital).
Formal N-of-1 statistical tests were performed in order to
test CT differences between each of the affected
carriers with imaging data (case 1 and case 3; case 2 was
unable to tolerate MRI) against 41 non-relative, unaffected,
non-carriers within the Scottish Mental Healthy
Family (SFMH) who were used as the normative compar-
ison group. To remove any confounding effects of age or
gender on CT values, both groups were matched as closely
as possible (cases versus control; mean age= 35.5 ver-
sus 38.3 years; %Female:Male ratio= 50:50 versus 44:56,
respectively). False discovery rate (FDR) correction for
multiple comparisons was applied across measures of
CT for each comparison. For direct comparison to the
most severely affected carrier (case 1), we have shown a
representative MRI scan of an unaffected, non-carrier par-
ticipant within the SFMH study, who has been
matched for age (47 and 45 years of age, respectively)
and gender (both female) (Fig. 1b). We also included
MRI scans from three healthy unaffected non-carrier rela-
tives from within the 16p13.11 duplication families
and these do not show any deficits in cortical thickness
(Fig. 1c).
Reprogramming fibroblasts to generate iPSC and
three germ layer differentiation
Human iPSC were derived from donor skin fibroblasts
using integration-free episomal methods [27] (see supple-
mentary methods). Control 5 was generated by retrovirally
reprogramming fibroblasts [28]. To validate differentiation
capacity of iPSCs, we performed in vitro differentiation into
three germ layers: endoderm, mesoderm, neuroectoderm as
detailed in supplementary methods.
NPC proliferation assays: EdU labeling and detection
Anterior NPCs (aNPCs) were derived from parental iPSC
lines as detailed in supplementary methods. Following plate
down in RosV2 F10 [Advanced-DMEM/F12, 1% P/S, 1%
Glutamax, 1% N-2, 0.5% B-27, supplemented with 2.5 ng/
mL FGF-2] media was changed to default [Advanced-
DMEM/F12, 1% P/S, 0.5% Glutamax, 0.5% N-2, 0.2% -
B-27, 2 μg/mL Heparin (Sigma)] to remove the effects of
mitogens. To assess NPC proliferation mitotic cells were
grown to ~50% confluency (to ensure consistency in
experimental conditions) and labelled with 10 μM ethynyl
deoxy-uridine (Click-IT EdU, Life Technologies) for 4 h.
Media was replaced completely and cells cultured for an
additional 4 h in the absence of EdU before fixation using
4% paraformaldehyde (PFA) (Sigma). Cells were permea-
bilised using 0.5% Triton X-100 (Sigma) in PBS for
20 mins and detected using the EdU detection kit (Ther-
moFisher) according to manufacturer’s instructions. NPCs
were also immunolabelled for Nestin and Pax-6 (see Sup-
plementary Table 2 for antibody details). Coverslips were
washed and mounted using ProLong Gold antifade moun-
tant with 4′,6-Diamidine-2′-phenylindole dihydrochloride
(DAPI) (ThermoFisher).
Cerebral organoid experiments
Cerebral organoids were generated and maintained
according to published protocols [29, 30] with the following
minor modifications. hiPSCs were cultured in Matrigel-
coated plates in E8 medium (Life Technologies). When
confluent, they were lifted into a 6 well plate in Phase I
medium using dispase/collagenase treatment. They were
grown in 10 cm dishes containing Phase I medium for
7 days and then changed to EB1 medium [A-DMEM/F12;
1% PSF; 1% Glutamax; 1% N-2; 500 μL B-27; 12.5 μL
FGF-2] for a further 2–4 days depending on the nature of
cells. After onset of rosette patterning embryoid bodies
(EBs) were collected in a 15 mL falcon tube, media was
removed and replaced with EB2 medium [same as EB1
except it contains B-27 without vitamin A and NEAA] in a
fresh 10 cm dish. Thereafter, EBs were cultured in EB3
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media (Same as EB2, except contains B-27+Vitamin A
and 1% Matrigel) which was changed every second day.
Cultures were grown on a digital orbital shaker (Heathrow
Scientific). Tissue was processed and analysed as described
in supplementary methods.
RNA sequencing
RNAs were isolated using the RNeasy Mini kit (QIAGEN).
RNA-seq samples were prepared from 12 NPC lines [8
control and 4 case lines comprising: control 1 (2 iPSC
1
esa
C
1l ort no
C
Coronal Sagittal
S
FM
H
 C
on
tro
l
b
a
Neuralisation
Drug screen
Lentivirus 
(pseudoviral particles
expressing NFkBp65)
3
esa
C
c
Organoid 
immunohistochemistry: 
Precursor cell proliferation & 
cell-division studies in 3D 
culture
Partially rescue cellular phenotype 
targetting dysregulated pathways 
using small molecular weight drugs 
and gene expression
Cellular & Molecular 
Studies
Transcriptomic & Proteomic 
Studies: Identification of shared 
differentially expressed RNA & 
proteins in NPCs
Induce Neuroectoderm
Cerebral Organoids
Cerebral Organoid Studies
NPC Proliferation Studies
Culture Embryoid 
Bodies (EBs)
Induced-Pluripotent 
Stem Cells (iPSCs)
Neuronal 
Precursor Cells 
(NPCs)Brain 
Imaging
Control 
Lines
Chr16p13.11 
Dup Cases
Ca
se
 1
Ca
se
 3
Fa
mi
ly C
on
tro
ls (
N=
3)
SF
MH
 Co
ntr
ols
 (N
=4
1)
2.0
2.2
2.4
2.6
2.8
3.0
G
lo
ba
l c
or
tic
al
 th
ic
kn
es
s 
(C
T)
a
d
2D cellular studies
3D cellular studies
Ca
se
 1
Ca
se
 3
Po
ole
d C
on
tro
ls
4.5
5.0
5.5
6.0
6.5
7.0
Te
m
po
ra
l c
or
tic
al
 th
ic
kn
es
s 
(C
T) *
*
M. Johnstone et al.
clones, from which one NPC line was derived from clone 1
and 2 NPC lines from clone 2, i.e. a total of 3 RNA samples
were sequenced from control 1); control 2 (1 iPSC clone
was derived into 1 NPC line from which 1 RNA-seq sample
was prepared); control 3 (1 iPSC clone from which 2 NPC
lines were derived providing 2 RNA-seq samples); control 4
(1 iPSC clone from which 1 NPC line was derived pro-
viding 1 RNA-seq sample); control 5 (1 iPSC clone from
which 1 NPC line was derived providing 1 RNA-seq
sample); case 1 (3 iPSC clones were generated and derived
to NPCs from which 2 were used for RNA-seq); case 2 (2
iPSC clones were generated and derived to NPCs from
which 1 was used for RNA-seq); case 3 (2 iPSC clones were
generated and derived to NPCs from which 1 was used for
RNA-seq); see Supplementary Table 3 for the specific lines
used]. Genomic DNA was removed with the DNA-Free kit
(Ambion). Analysis was performed as described in supple-
mentary methods.
Reverse-phase protein arrays (RPPAs)
RPPA is a miniaturised, highly sensitive, quantitative “dot-
blot” immunoassay where the analyte (from cell lysates) is
immobilised on a solid phase (nitrocellulose) and subse-
quently probed with antibodies to specific targets (Fig. 4a)
[31, 32] ideally suited to elucidate mechanisms-of-action
and phenotypic response in 2D and 3D models [33]. Forty
candidate intracellular signalling molecules were examined
(see Supplementary Table 4). The specific lines used in
RPPA experiments are detailed in Supplementary Table 3.
Samples were prepared as described in supplementary
methods.
Screening of small-molecule activators of NFκB p65
Two small molecular weight activators of NFκB p65 (SRI-
22772 and SRI-22782; denoted Compounds 1 and 2,
respectively) previously shown to result in non-canonical
activation of NFκB p65 in neurons [34] (ChemBridge
Corporation, San Diego, California) were solubilised in
100% DMSO (Sigma) at a concentration of 5 μg/mL. As a
positive control NPCs were treated with TNF-α (Peprotech)
at 100 ng/mL.
Transient transfection of NPCs with NDE1
pcDNA3.1NDE1-WT-V5 construct was generated by
amplifying cDNA fragments encoding C-terminally V5-
tagged wild-type human NDE1 using pDEST40 NDE1
constructs as templates, digested with BamHI/NotI restric-
tion enzymes then inserted into the BamHI/NotI site of
pcDNA3.1 (ThermoFisher) as described previously [35].
NPCs were transiently transfected using an Amaxa
Nucleofector device (Lonza). Briefly, 5 × 106 cells were
lifted with accutase, pelleted by centrifugation (200×g for 5
min), washed with PBS and resuspended in 82 μL of
Amaxa nucleofection solution with 18 μL of Amaxa
nucleofection supplement 1. Cell suspensions were trans-
ferred to 1.5 mL Eppendorf tubes with 5–10 μg of plasmid
DNA (either pcDNA3.1NDE1-WT-V5 or pcDNA3.1 plas-
mid alone control). The cell–DNA mix was transferred to an
Amaxa cuvette, and electroporation was carried out using
programme “A-033”. Cells were then plated in default
media on poly-ornithine (Sigma), laminin (Sigma), fibro-
nectin (Sigma) and Matrigel-coated coverslips and left for
48 h to recover post-transfection. NPC proliferation assays
were then performed using the Click-IT EdU kit (Thermo-
Fisher) as described above but left for an extended period of
10 h. Cells were fixed and stained as described or lifted with
accutase, washed and centrifuged for preparation of cell
lysates for immunoblotting as described in supplementary
methods.
Lentivirus treatment of NPCs
A total of 100 μL of lentivirus (production detailed in sup-
plementary methods) was mixed with 4 μg/mL of polybrene
(Merck) and used to infect 1 × 106 NPCs grown in 2 mL of
media. The cells were incubated with the virus for 6 h at
37 °C. Thereafter, the virus containing media was disposed
and replaced with fresh media and NPCs were left for 48 h.
Cells were then processed for cell proliferation assays as
Fig. 1 Overview of the study design and MR imaging shows cortical
deficits in carriers of the chr16p13.11 duplication. a Schematic sum-
mary of the study. b Coronal and sagittal MRI views demonstrate
significant volume reduction of cortical brain tissue in an affected
carrier of the 16p13.11 microduplication (case 1) evident in both the
coronal (areas of significant cortical volume reduction are marked by
red arrows) and sagittal views. Representative scans are also shown
from an in-family control (control 1) and from an age and gender
matched participant in the Scottish Mental Health Research study
(SFMH) control group. Representative MRI images are also shown for
case 3. Case 2 was unable to tolerate the MR scan due to extreme
anxiety and agitation. c Global cortical thickness measures show sig-
nificant differences between case 1 and a group of 41 control indivi-
duals from the SMHR study. Significance testing on the differences
between case 1’s score and the SFMH control sample are as follows
based on N-of-1 statistics [67]: control sample t=−2.305; one-tailed
probability= 0.013; two-tailed probability= 0.026. Estimated per-
centage of normal population falling below individual's
score= 1.32%. 95% lower confidence limit on the
percentage= 0.17%. 95% upper confidence limit on the
percentage= 4.14%. The value for mean global CT is also marked in
this graph for case 3. d Temporal lobe cortical thickness measures
show significant differences between cases 1 and 3 and a group of 41
control individuals from the SMHR study
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described above or lifted with accutase, centrifuged, washed
in PBS and cell pellets were processed for immunoblotting.
Results
Reduced cortical thickness in chromosome 16p13.11
microduplication carriers
To study the impact of 16p13.11 microduplications on
cortical thickness in humans, we undertook structural MRI
scanning alongside human stem cell studies (Fig. 1).
Structural MRI scans show marked cortical deficits in the
coronal and sagittal planes, particularly in the frontal lobe
compared to controls (Fig. 1b–d). Case 1 demonstrated
significantly reduced CT globally, and in frontal and par-
ietal lobar regions versus controls (t=−2.31, p= 0.01,
t=− 1.88, p= 0.03, pcorr= 0.04, t=−2.06, p= 0.02,
pcorr= 0.04, global, frontal and parietal, respectively,
Fig. 1c). Both case 1 and case 3 demonstrated significantly
reduced CT in the temporal lobe versus the healthy com-
parison subjects (Fig. 1d) (case 1: t=−2.13, p= 0.02,
pcorr= 0.04; case 3: t=−4.04, p= 0.00, pcorr < 0.01).
Proliferation deficits in case-derived NPCs
To determine the cellular and molecular basis underlying
the observed abnormalities in cortical volume, we next
established multiple iPSC lines, using episomal methods,
from three affected individuals (from two families pre-
viously identified [7]) carrying 16p13.11 microduplications
in one chromosome (cases 1–3) and from five control
individuals, including two from the same family as cases 2
and 3 (Supplementary Table 1 and Supplementary Fig-
ure 1b and c). All iPSCs were karyotypically normal,
expressed pluripotency markers and showed three germ
layer differentiation (Supplementary Figure 1a and 2).
Long-term propagated monolayer cultures of anterior NPCs
displayed rosette-like patterns with typical NESTIN and
OTX2 expression (Supplementary Figure 3a-b). When
aNPCs were differentiated by plate down in default media
supplemented with forskolin, BDNF and GDNF (Supple-
mentary Figure 3c-d), immunocytochemistry at 35 days
revealed predominantly neuronal cultures (assessed by
MAP2 staining) with <15% astrocyte (assessed by GFAP
staining)(Supplementary Figure 3e).
In view of evidence that mutations in genes, particularly
NDE1, in the microduplication are associated with abnor-
mal neurogenesis and cortical lamination, we determined
levels of NDE1 in NPCs [9, 19] (Supplementary Figure 4).
This showed that patient iPSC-derived NPCs carry (i) three
copies of NDE1 at the genomic level (by digital-drop PCR),
(ii) approximately 1.5× mRNA (by RT-qPCR) and (iii)
1.5× NDE1 protein by immunoblotting (Supplementary
Figure 4b-d). Our RT-qPCR experiments also showed that
several other genes within the chromosome 16p13.11
microduplication, in particular NTAN1, PDXDC1 and
ABCC1 were also ~1.5× elevated at the mRNA level in
cases compared to controls. We next compared proliferation
of early passage (6–12) NPCs between cases and controls
following plating in the absence of mitogens. Significantly
reduced NPC proliferation, measured by Edu Click-It
assays, was found in all cases when compared individu-
ally (Fig. 2a, b) or as pooled data to control NPCs (Fig. 2c).
Case 1 appeared to exhibit the most pronounced prolifera-
tion deficits compared to controls mirroring the severity of
the changes seen in the MRI of case 1.
To determine whether these observed proliferation defi-
cits in cases were dependent on NDE1 levels, we transiently
transfected V5-tagged full-length human NDE1 into NPCs
from controls 2 and 3 (Fig. 2d). Importantly, the miR-484
sequence, encoded within the 5′UTR of the NDE1 gene
itself, is not included in this construct as the NDE1 gene
was sub-cloned using a 5′ amplification primer that was
downstream of the miR-484 yet immediately upstream of
the start codon of NDE1 [36]. NDE1 was widely distributed
throughout the cytoplasm of NPCs in a punctate pattern
(Fig. 2d). Successful transfection was also confirmed by
quantitative immunoblotting (Fig. 2e). Proliferation assays
revealed control lines 2 and 3, overexpressing full-length
human NDE1, showed significantly less proliferation
(31.3% EdU/DAPI for NDE1 transfected NPCs compared
to 51.98% for controls, p= 0.0036, paired t-test) (Fig. 2f).
Together these findings suggest that reduced NPC pro-
liferation in control NPCs are most likely due to the over-
expression of NDE1 and not the miR-484.
Smaller cerebral organoids display altered planes of
cell division of radial glial progenitors in 16p13.11
microduplication carriers
In view of the twin observations of global cortical thinning
in patient MRI scans and reduced NPC proliferation in
patient-derived 2D cultures, we next grew 3D cerebral
organoids (Fig. 2g). Cerebral organoids formed large con-
tinuous neuroepithelia surrounding a fluid-filled cavity
reminiscent of a ventricle with characteristic apical staining
of the neural specific N-cadherin (Supplementary Fig-
ure 5a). Immunohistological analysis revealed upregulation
of the anterior brain markers FOXG1 and PAX6 indicating
successful neural induction (Supplementary Figure 5b-c).
Significantly smaller organoids were observed at 1 month
from cases, especially case 1, compared to controls (Fig. 2h;
p < 0.0001, ordinary one-way ANOVA with Dunnett’s
multiple correction test), reminiscent of the reduced brain
size seen in the patients, especially case 1 (Fig. 1b), and the
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reduced proliferation of NPCs in cases compared to con-
trols, with case 1 again showing the most pronounced
deficit (Fig. 2a–c). Immunohistochemical staining of
progenitors (Fig. 2i) and neurons (Supplementary Fig-
ure 5d) at 1 month also revealed far fewer neuronal
progenitor cell regions and reduced numbers of total
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dividing neuronal progenitor cells in cerebral organoids as
assessed by quantitative phospho-histone H3 (Ser10) and
phospho-vimentin staining in all three affected carriers
compared to controls (Fig. 2j; 84% reduction in proliferat-
ing cells per unit area of organoid from case 1; 93%
reduction in case 2 and 40% reduction in case 3 compared
to control-derived organoids; p < 0.0001, ordinary one-way
ANOVA with Dunnett’s multiple correction test). Impor-
tantly, we were able to demonstrate recapitulation of cor-
tical organization revealing typical arrangement into a layer
reminiscent of the ventricular zone (VZ) with neurons
located on the basal surface (Supplementary Figure 5d).
Mitotic radial glia staining (phospho-histone H3) in cortical
regions of 1-month-old cerebral organoids reveals ven-
tricular radial glia (vRG) undergoing mitosis at the apical
membrane whereas outer radial glia (oRG) undergo mitosis
outside the ventricular zone. Radial glia in the ventricular
zone are marked by SOX2 staining (Supplementary Fig-
ure 5d). Approximately 85% of P-His+ve cells are vRG
cells and 15% are oRGs (±5.8%, n= 30).
RGPs constitute the majority of stem cells in the human
neocortex and are highly elongated cells with an apical
process in contact with the ventricular surface and a basal
process in contact with the outer surface of the brain during
development. The plane of division of RGPs is known to
determine the fate of the daughter cells [37, 38]. We
examined spindle-orientation in organoids by staining for
phospho-histone H3 or phospho-vimentin, and classified the
progenitors as having one of three positions relative to the
ventricular surface: vertical, oblique or horizontal [37]
(Fig. 2k). Control organoid tissue examined at 1 month of
age showed exclusively vertical (60–90 degrees) and obli-
que (30–60 degrees) orientations. No horizontal orientations
were observed in control organoids (Fig. 2l). In contrast, up
to 20–42% of vRG were in a horizontal orientation (0–30
degrees) in case-derived lines. This switch to horizontal
orientations may explain the patient phenotype of reduced
cortical volume on MRI and reduced organoid size as
symmetrical vRG division is important for progenitor self-
renewal and determines cortical thickness formation during
development [39]. Asymmetrical division on the other hand
causes premature differentiation of one of the daughter cells
to a neuronal fate thereby reducing the pool of progenitor
cells and resulting in cortical thinning (schematic figure in
Fig. 2l).
Transcriptomic and proteomic analysis of case-
derived NPCs and cerebral organoids identifies
perturbations in the NFκB p65 pathway
To explore potential molecular mechanisms underlying
reduced NPC proliferation, we next undertook RNA-
sequencing analysis (Fig. 3). Applying a FDR of 0.05,
there are 994 differentially expressed genes between pooled
case and control NPCs. Expression fold changes of the top
Fig. 2 Proliferation studies of NPCs and cerebral organoids. a
Representative images of the mean proliferation values of case 1
compared to control 1. Scale bar: 50 µm. NPCs from case and control
lines were plated down and grown in default media for 7–10 days prior
to Click-IT EdU proliferation assays being undertaken. b NPCs from
affected cases carrying the Chr16p13.11 microduplication show sig-
nificantly reduced proliferation compared to control lines. Two NPC
lines derived from two independent iPSC clones from each case were
compared to a panel of NPC lines derived from five control indivi-
duals. c Graph showing values for pooled control NPC lines compared
to pooled case NPC lines. Graphs shows mean ± sem, controls: 31.26
± 1.14%, cases 10.5 ± 0.298%, ****p < 0.0001 (unpaired two-tailed
t-test with Welch’s correction). d NPCs from control individuals
(control 2 and 3) were transfected either with full-length human V5-
tagged NDE1 (pcDNA3.1NDE1-WT-V5 construct) or with the plas-
mid alone (pcDNA3.1). NDE1 staining shows intense signal of NDE1
in the cytoplasm of cells which had been transfected with the NDE1-
V5 construct compared to NPCs transfected with control plas-
mid. e Immunoblotting shows that NPCs, derived from healthy con-
trols and transfected with pcDNA NDE1-WT-V5 construct, expressed
significantly more NDE1 compared to NPCs transfected with
pcDNA3.1-control plasmid alone. f Proliferation assays post-trans-
fection: Electroporated cells were plated down and 48 h later EdU was
added to measure the proliferation rate of transfected cells (right hand
panel of d). f Graph shows that cells transfected with full-length wild-
type human NDE1 display significantly reduced proliferation over a
10-h time-period compared to empty vector transfected cells. Graph
shows mean ± sem, **p < 0.005 (p= 0.0036, paired t-test; mean=
51.98% EdU/DAPI for empty vector control transfected NPCs com-
pared to mean= 31.3% EdU/DAPI for NPCs transfected with full-
length NDE1). g Representative images of cerebral organoids from
controls and cases at 1 month of age. Scale bar: 1000 μm (1 mm). g
Plot of organoid sizes (organoid area μm2) from controls and cases at
1 month. Data represented as box plots with central bar representing
mean ± sem shown by whiskers; ****p < 0.0001, ordinary one-way
ANOVA with Dunnett’s multiple correction test. Case 1 organoids are
significantly smaller than controls (mean area of 326,550 μm2 for case
1 organoids compared to mean of 1,364,157 μm2 for controls. Case 2
and 3 organoids were less severely stunted in their growth rates with
mean areas of 973,586 and 856,846 μm2, respectively). Organoid n=
30+ per case. i Representative images of proliferative zones of 1-
month-old organoids from control compared to case iPSC lines. Scale
bar: 50 µm. j Graph of proliferating cells (P-His+ve) quantified in
sectioned organoids showing pooled values of different clones for each
case. Organoids were sectioned, stained and quantified using Image J
by two independent blinded examiners. Family control organoids are
from n= 3 individuals. Data represented as mean ± sem; ****p <
0.0001, ordinary one-way ANOVA with Dunnett’s multiple correction
test. Chr16p13.11 microduplications result in a switch from symme-
trical to asymmetrical cell division. k Schematic diagram illustrating
RG division in one of three orientations: 60–90 degrees (vertical); 30–
60 degrees (oblique) and 0–30 degrees (horizontal). l Cerebral orga-
noids were sectioned and stained with antibodies to phospho-histone
H3 and/or phospho-vimentin. Quantification of RG division orienta-
tions is displayed in pie charts next to representative images for case
and control organoids examined showing the proportion of cells in one
of three bins (vertical, oblique or horizontal) n= 30–50 anaphase cells
from a minimum of five cerebral organoids from each line. Schematic
diagram (right) illustrating potential consequences to cortical thickness
following a switch from symmetric to asymmetric cell division in
affected carriers of Chr16p13.11 microduplications
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20 most significant up and downregulated genes are shown
(Supplementary Figure 6a) and all differentially expressed
genes are listed in Supplementary Table 4. GO enrichment
analysis (Fig. 3c–e, respectively) showed the most sig-
nificant downregulation of genes associated with positive
regulation of I-kappaB kinase/NF-kappaB signalling
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(biological processes), as well as focal adhesion, regulation
of cell shape, actin filament network, cytoskeleton (cellular
components), and alpha-L-arabinofuranosidase activity
(molecular function). Transcriptomic data (Supplementary
Table 4) also confirmed differential expression of genes
associated with the chr16p13.11 microduplication including
NDE1, NTAN1, PDXDC1, and ABCC1 that we had sepa-
rately shown by RT-qPCR (Supplementary Figure 4b). We
have also carried out differential expression analysis for
each case separately compared to controls (Supplementary
Tables 6–8). All cases exhibit a similar overall pattern of
differential gene expression changes as discussed above for
the pooled case data. Case 3, however, appears to also have
a larger number of differentially expressed genes and a
number of these appear to be related to the cell cycle.
RNA-seq data was also analysed to assess whether the
set of differentially expressed genes we found in our cell
studies was significantly enriched for miR-484 targets pre-
viously reported [25]. We used the miRWalk 2.0 database
[40] (http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/
index.html) to obtain the 2588 gene targets of miR-484,
which are predicted by at least 50% of the 12 prediction
programmes used by the database. We then looked to see if
our set of 1012 differentially expressed genes was enriched
in miR-484 targets, as compared to the background set of
genes expressed in our RNA-seq data. Fisher’s exact test
(one-sided) gave a small enrichment, with an odds ratio
(OR) of 1.38 (p= 0.003) for targets of miR-484 among the
genes with adjusted p-value < 0.05. To determine whether
enrichment of our key GO term (positive regulation of I-
kappaB kinase/NF-kappaB signalling) and enrichment of
miR-484 targets remains significant and maintained if we
impose higher FPKM cut-offs we have plotted (i) the p-
value for enrichment via GO analysis of the top down-
regulated GO term ‘Positive regulation of I-kappaB kinase/
NF-kappaB signalling’ in differentially expressed genes
above this cut-off versus all genes above this cut-off and (ii)
the p-value for enrichment of miR-484 targets in
differentially expressed genes above this cut-off versus all
genes above this cut-off p-values plotted as −log10(p)
(Supplementary Figure 6b). While the GO term ‘Positive
regulation of I-kappaB kinase/NF-kappaB signalling’
enrichment (blue line) remains below p= 0.05 (as indicated
by the black horizontal line, above which values are sig-
nificant) as the FPKM cut-off increases, the miR-484
enrichment (red line) is already non-significant at a cut-off
of FPKM > 0.5 (Supplementary Figure 6b).
Using reverse-phase proteomic array (RPPA) [32], we
validated findings from the RNA-seq analysis in NPC
lysates. Candidate antibody arrays were selected as per
relevance to several of the aforementioned signalling path-
ways, in particular NFκB and extracellular matrix signalling
(Supplementary Table 4). Three replicates were tested in
RPPA (Fig. 4a) for each cell line, plotted individually by
antibody and displayed in a heat plot (Fig. 4b). Anti-
phospho-NFκB p65 (Ser536) showed the greatest differ-
ential expression of all proteins assayed, with pooled data
revealing over 50% reduction in cases (Fig. 4c), confirmed
also by immunoblotting with the anti-phospho-NFκB p65
(Ser536) antibody (Fig. 4d). We also probed blots with an
antibody to total NFκB p65 (Fig. 4e) and show the relative
phosphorylation levels at Ser536 normalized by total NFκB
p65 expression levels for each case compared to controls
(Fig. 4f). All three cases show over 50% reduction
compared to controls by quantification of immunoblots
(Fig. 4f). Immunostaining showed that NFκB p65 expres-
sion [as detected by two antibodies to total NFκB p65 and
an antibody specific to phospho-NFκB p65 (ser536)] is
localised to the apical surface of the ventricular zone in
organoids (Fig. 4g and Supplementary Figure 5g-i), an area
that co-localises with NPC proliferation and NDE1
expression (Supplementary Figure 5h-i). All organoids
derived from cases had significantly less NFκB p65 in the
proliferative zones compared to organoids derived from
controls (Fig. 4h, i; case organoids showed approximately
79.7% reduction in NFκB p65 staining compared to control
organoids; p < 0.0001, Mann–Whitney test).
NPC proliferation deficits can be rescued by up-
regulating expression of NFκB p65
To investigate whether it is possible to rescue the NPC
proliferation deficits by targeting the NFκB p65 pathway we
utilised recently described small molecular weight com-
pounds that up-regulate NFκB p65 expression and activity
in a non-canonical, cytokine receptor-independent manner
[34]. Two commercially available lead compounds, SRI-
22772 and SRI-22782, were chosen. Both have heterocyclic
structures and are denoted compound 1 and 2 for the pur-
poses of this study (Fig. 5a). First, we treated case and
control NPCs with both compounds at concentrations (10
Fig. 3 RNA-sequencing data highlights differences in I-kappaB kinase
and NF-kappaB signalling pathways as well as focal adhesion, reg-
ulation of cell shape, actin filament network, cytoskeleton, and alpha-
L-arabinofuranosidase activity. a Representation of the differential
expression results. Each cross is a gene, plotted with its mean abun-
dance (measured in “fragments per kilobase per million mapped reads”
(FPKM)) in cases versus controls. Very low abundance genes (those
with mean FPKM across all samples < 0.5) have been filtered out. Red
crosses are those genes that were called as differentially expressed.
Genes with zero mean FPKM are drawn superimposed on the axes. b
Heatmap of differentially expressed genes. Colours indicate log2(gene
abundance in sample/mean abundance for this gene). Ordering is from
most downregulated in cases to most upregulated. Graphs showing the
most significantly downregulated (blue) or upregulated (red) gene
ontology (GO) terms for (c) biological processes, (d) cellular com-
ponents and (e) molecular function
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and 1 μM, respectively) that had been shown to cause
optimal non-canonical long-lasting NFκB p65 activation
[34]. We studied the ability of these two lead compounds to
cause translocation of NFκB p65 to the cell nucleus, using
TNF-α as a positive control [34], in 2D NPC cultures
(Fig. 5c). Following 24-h exposure to both compounds,
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there was significant NFκB p65 nuclear translocation as
detected by immunofluorescence that was confirmed by
quantitative immunoblots of nuclear fractions (Fig. 5d, e).
Moreover, compound 2 was significantly more effective at
increasing nuclear NFκB p65 compared to both TNF-α and
compound 1. Having established functional efficacy of
compounds 1 and 2 to activate NFκB p65 signalling, we
next asked whether treatment of 16p13.11 microduplication
carrier-derived NPCs (from cases 1, 2 and 3) with com-
pound 1 or 2 would correct the observed mutation-
dependent reduction in NPC proliferation. EdU prolifera-
tion assays were undertaken following treatment of case
NPCs with TNF-α alone, compounds 1 and 2 for 24 h
(Fig. 5f, g shows pooled data; Supplementary Figure 7a-b
shows representative images and graphs from each of the
three individual cases studied). Compared to controls
(DMSO vehicle-treated only), TNF-α and compounds 1 or 2
resulted in significantly increased NPC proliferation, back
to a level that was observed in NPCs derived from healthy
individuals (~35–40% EdU/DAPI over an 8-h time course
of proliferation; p < 0.0001, ordinary one-way ANOVA
with Dunnett’s multiple comparison test). We ruled out an
alternate mode of action of these compounds by ectopically
expressing NFκB p65 in 16p13.11 microduplication carrier
patient-derived NPCs using a lentivirus construct.
Overexpression of NFκB p65 produced an effect similar to
that of compound 2 as judged by EdU uptake assay thus
showing that a rescue of NFκB p65 was sufficient to reverse
the 16p13.11 microduplication dependent change in NPC
proliferation (Fig. 5h, i).
Discussion
Human iPSC models when applied to genetically
stratified cohorts are powerful tools to dissect the mole-
cular and cellular underpinnings of neurodevelopmental
disorders [20, 41–44]. Here, we have undertaken linked
imaging and stem cell studies in a local cohort with a rare
highly penetrant 16p13.11 CNV that shows a striking
threefold overrepresentation in SCZ cases compared to
controls [3, 7]. This study demonstrates a potential role
for genes within the chromosome 16p13.11 micro-
duplication (and NDE1 in particular) in human cortico-
genesis and implicates dysregulation of NFκB as an
important mechanistic pathway in neurodevelopmental
disorders.
Until recently, the study of human brain development
was severely restricted by availability of human post-
mortem foetal tissue leading to a reliance on rodent models
for mechanistic understanding of the role of NDE1 in reg-
ulating NPC proliferation, migration and cortical thickness.
Nde1 mutant mouse studies have revealed various pheno-
types including thin superficial cortical layers (II to IV) [19]
and catastrophic DNA double strand breaks concurrent with
DNA replication, leading to p53-dependent apoptosis and
reduced neurons in cortical layer II/III [45]. More recently
knockdown in rat using in utero electroporation confirmed
these findings and show that Nde1 effects are pronounced
on premitotic nuclear migration with specific effects on
radial glial progenitor cells and on primary cilia [46]. It has
recently been shown that in utero electroporation of
NDE1 short hairpin RNA (shRNA) in embryonic rat brains
causes apical interkinetic nuclear migration defects and that
the severity of NDE1-associated microcephaly results not
from defects in mitosis but rather the inability of neural
progenitors to ever reach this stage [46]. This is consistent
with our findings of reduced cortical thickness upon struc-
tural MRI, and decreased and abnormal (symmetric versus
asymmetric) divisions of neural progenitors in human case-
derived organoids. Our study emphasizes the importance of
human experimental system to investigate neurodevelop-
mental disorders furthering what has previously been
reported in animal studies by allowing us to directly link
human MRI brain scanning data with human cellular and
molecular data in both 2D and 3D cellular systems from the
same patients. Specific findings in this study, that have not
been reported in animal studies, is the identification of a
Fig. 4 NFκB p65 protein levels are significantly downregulated in
NPCs and cerebral organoids from cases compared to controls. a
Schematic overview of RPPA. b RPPA heatmap for the pooled data,
i.e. each block is representing the value log2(protein abundance in
line/mean abundance for this protein). Data are ordered by decreasing
values of (mean protein abundance in cases)/(mean protein abundance
in controls). Note that NFκB appears as the top “downregulated”
protein in the cases. c Graph of anti-phospho-NFκB p65 (Ser536)
expression in NPCs from case lines versus control lines determined by
RPPA (Note that in the RPPA experiments we tested 2 clones for each
of cases 1, 2 and 3; 2 clones for control 1; and one clone each from
controls 2, 3 and 5. Each clone was run in triplicate). Statistics: mean
± sem is shown; *p= 0.05; **p < 0.005 (ordinary one-way ANOVA
with Dunnett’s multiple comparisons test). d Immunoblot of cell
lysates from case-derived NPCs compared to controls stained with
anti-phospho-NFκB p65 (Ser536) and anti-vinculin loading control
antibody. e Immunoblot of cell lysates from case-derived NPCs
compared to controls stained with total NFκB p65 antibody and anti-
vinculin loading control antibody. f Quantification of immunoblots
showing anti-phospho-NFκB p65 (Ser536) normalized by total NFκB
p65 in pooled cases compared to controls. Statistics: mean ± sem is
shown; *p= 0.05 (ordinary one-way ANOVA with Dunnett’s multiple
comparisons test). g Representative images of proliferative zones of 1-
month-old organoids from individual control iPSC lines compared to
individual case lines stained with anti-NFκB p65 (red). Scale bar: 100
µm. h Graph of NFκB p65 staining of cerebral organoids from three
individual cases compared to three individual controls and also i graph
of NFκB p65 staining of cerebral organoids from pooled cases com-
pared to pooled controls. Raw integrated density (the sum of the values
of the pixels per unit area of organoid) was determined by capturing
organoid images at the same magnification and calculated using Image
J. Statistics: mean ± sem is shown; **p < 0.005; ***p < 0.0005;
****p < 0.0001 (Mann–Whitney test)
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potential role for NFκB p65 in this process. Unbiased
transcriptomic and proteomic data has shown significant
differences in expression of NFκB p65 between cases and
controls and furthermore it has been possible to rescue this
in vitro in human-derived cells both genetically and
pharmacologically.
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Several independent studies have implicated chromo-
some 16p13.11 microduplication and the NDE1 gene as
underlying contributors to mental illness and abnormal
corticogenesis in humans [3, 21, 22] and rodent [9–14]
models, respectively. More recent studies have suggested
that a microRNA-484, encoded within the 5’UTR of NDE1
may be the causative factor in the locus [8, 25], whereas
others had previously proposed that NDE1 and NTAN1
were the two most likely genes to be responsible [3]. Our
data overexpressing the NDE1 gene alone (without the miR-
484) in control human-derived NPCs shows that it is pos-
sible to recapitulate the proliferation deficit seen in case-
derived lines suggesting that an extra copy of the NDE1
gene is in itself responsible. Using our RNA-sequencing
data, we also looked to see if our set of 1012 differentially
expressed genes was enriched in miR-484 targets that have
been previously described [25]. Fisher's exact test (one-
sided) gave a small enrichment, with an odds ratio (OR) of
1.38 (p= 0.003) for targets of miR-484 among the genes
with adjusted p-value < 0.05 in our RNA-sequencing data.
However, it is possible that this result is confounded by
other factors unrelated to the 16p13.11 microduplication.
Differential gene expression with RNA-seq data has, in
general, a greater likelihood to detect statistical significance
for genes that are more highly expressed or which have
longer transcripts; and it might be (to give one possible
example) that genes highly expressed in the brain are more
likely to be targets of miR-484. Indeed, if we impose a cut-
off of mean abundance over all samples > 1 FPKM, then the
enrichment for targets of miR-484 among the differentially
expressed genes was no longer observed (OR= 0.77,
p= 0.9797). However, one might also argue that, for
example, the enrichment we see for the GO term ‘Positive
regulation of I-kappaB kinase/NF-kappaB signalling’ in our
differentially expressed genes might actually be because
genes with that annotation also tend to be genes highly
expressed in the brain. If this were the case, we would
reasonably expect to see that this GO enrichment is main-
tained when we impose higher FPKM cut-offs. We have
indeed demonstrated this where, for various mean FPKM
cut-offs, we have plotted the p-value for enrichment via GO
analysis of the top downregulated GO term ‘Positive reg-
ulation of I-kappaB kinase/NF-kappaB signalling’ in dif-
ferentially expressed genes above this cut-off versus all
genes above this cut-off and the p-value for enrichment of
miR-484 targets in differentially expressed genes above this
cut-off versus all genes above this cut-off [p-values are
plotted as −log10(p)]. Enrichment of the GO term ‘Positive
regulation of I-kappaB kinase/NF-kappaB signalling’
remains significant regardless of the cut-off, whereas the
mir-484 enrichment is already non-significant at a cut-off of
FPKM > 0.5. Taken together with our data showing that
overexpression of NDE1 affects cell proliferation of NPCs,
these data argue against the miR-484 being the causative
factor for differentially expressed genes in human NPCs.
It is also possible that genes within the chromosome
16p13.11 locus exert their effect in combination with other
genes elsewhere in the genome as has recently been pro-
posed in 22q11.2 deletion syndrome where it has been
suggested that additional rare CNVs, overlapping genes
outside the 22q11.2 deletion region, contribute to schizo-
phrenia risk supporting a multigenic hypothesis for schi-
zophrenia [47]. In this regard, it is noteworthy that case 3
carries both the 16p13.11 microduplication and also a de
novo loss-of-function mutation in TSC2, yet demonstrates a
similar cellular phenotype to cases 1 and 2. Several pub-
lished clinical case reports describe patients with a combi-
nation of two rare genetic variants, one of which includes
16p13.11 duplications [48, 49] that has led to the proposal
of a ‘two-hit model’ in which the 16p13.11 duplication may
contribute to the phenotype, not only as a single event but
also in association with another mutation [48].
In this regard, it is also interesting to note that in terms of
clinical phenotype case 3 is perhaps the most severely
affected suffering from intellectual disability, ASD and
teenage onset schizophrenia. All three diagnoses could be
associated with either the 16p13.11 microduplication and /
or the TSC2 LoF mutation. Our RPPA data showed a
reduction in expression of mTOR protein and also mTOR
phosphorylated Serine 2448, in case 3 consistent with an
interplay between AKT, TSC2 and the mTOR complex [50]
and suggests the involvement of additional pathways in this
Fig. 5 NFκB p65 activator compounds cause p65 nuclear translocation
in NPCs and reverse the proliferation deficit in case-derived NPCs. a
Structures of NFκB p65 activators compound 1 (SRI-22772) and
compound 2 (SRI-22782). b NPCs (from controls and cases) were
plated down in default media (without mitogens) and 7–10 days later
TNF-α or compounds 1 or 2 were added to the media for 24 h. c NPCs
treated with either TNF-α (positive control) or compounds 1 or
2 showed significantly increased anti-phospho-NFκB p65 (Ser536)
localising to the nucleus compared to vehicle-treated. d Nuclear
extracts were prepared from NPCs treated with vehicle (DMSO con-
trol), TNF-α and compounds 1 and 2 and immunoblotted with anti-
phospho-NFκB p65 (Ser536). e Bands were quantified and normalised
to the levels of vinculin (loading control). Compound 2 treatment
resulted in significant increase in nuclear NFκB p65 Ser536 expression
(ordinary one-way ANOVA. Values plotted are the mean ± sem;
*p < 0.05; ns non-significant; ****p < 0.0001). f Representative ima-
ges of proliferation assays of case NPCs (case 1, clone 1) following
treatment with vehicle (DMSO), TNF-α, compounds 1 and 2. g Graph
showing proliferation of all case NPCs (pooled) showing significant
rescue of proliferation deficits following treatment with TNF-α and
compounds 1 and 2 (ordinary one-way ANOVA with Dunnett’s
multiple comparison test. Values plotted are the mean ± sem;
****p < 0.0001). Representative images of case NPCs infected with
NFκB p65 (RELA) Lentivirus or vector alone (control) demonstrate
that cells infected with RELA express increased NFκB p65 and exhibit
increased proliferation i compared to NPCs from the same patient
infected with the vector alone
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case. One limitation of stem cell studies, involving rare
highly penetrant variants associated with neurodevelop-
mental disorders, relates to the small numbers of affected
carriers actually studied. Future collaborative studies com-
paring cellular phenotypes and neuroimaging from larger
cohorts will be essential to confirm and extend the reported
findings.
RNA-sequencing data showed the most significantly
affected GO category in cases compared to controls was
downregulation of genes associated with positive regulation
of I-kappaB kinase/NF-kappaB signalling which has been
implicated in neurogenesis [51–55]. Our RPPA, immuno-
blotting and immunostaining data with anti-NFκB p65
antibodies confirmed these findings in human 2D NPC
cultures and also in human 3D cerebral organoid cultures.
The NFκB family contains 5 members including RelA(p65),
RelB, c-Rel, p50/p105 (NFκB1) and p52/p100 (NFκB2),
which form various combinations of homodimers or het-
erodimers [56] activated through a series of signaling cas-
cades. The most common form of NFκB in the brain is a
dimer of p50/p65 (RelA). Neurogenesis involves highly
controlled proliferation, survival, migration and lineage
differentiation of neural stem/progenitor cells (NSC/NPCs)
and is tightly regulated by intrinsic and extrinsic factors.
Embryonic p65−/− knockout mouse-derived NPCs display
significantly reduced growth compared to wild-type litter-
mates, an effect attributed to a reduction in the number of
proliferating cells [57]. NFκB signaling also regulates the
early differentiation of NSCs [58], with addition of TNFα to
activate NFκB signaling under proliferation conditions
sufficient to induce neural differentiation of NSCs/NPCs
[58]. The role of NFκB in both proliferation and initial
differentiation of NSCs highlights a novel potential target
for neurodevelopmental disorders characterized by dysre-
gulated NPC proliferation, neuronal specification and
lamination. Under physiologic conditions, moderate acti-
vation of NFκB signaling promotes NSC differentiation into
NPCs and maintains a continuous source for neurogenesis.
Transgenic mouse models have also highlighted that NFκB
in NSCs/NPCs is necessary for axogenesis and maturation
[59] yet, persistent and repeated overactivation of NFκB
signaling in NSCs may exhaust the NSC pool and thus lead
to reduced neurogenesis as seen in aging [60] and chronic
stress [61]. NFκB is not only important in neurogenesis but
a growing literature shows its importance in glial biology
and myelination in both the CNS and PNS [52–55].
Interestingly, maternal immune activation models such
as the polyIC mouse model also show activation of NFκB
following a single injection of polyIC during early gesta-
tional stages leading to dysregulated neural progenitor
proliferation amongst other effects [62]. In patients with
schizophrenia the expression of NFκB-responsive genes is
increased [63], and identification of three single-nucleotide
polymorphism variants of the p65 gene associated with
schizophrenia in a Japanese population provides further
indirect evidence implicating this pathway in neurodeve-
lopmental disorders [63]. Schizophrenia genome-wide
association studies (GWAS) have consistently implicated
genetic variants in the major histocompatibility complex
(MHC) on chromosome 6 as a susceptibility factor sug-
gesting that the immune abnormalities in schizophrenia may
have a genetic origin [64]. It has long been suggested that
stress, trauma and infection from conception onwards are
important aetiological risk factors in the development of
schizophrenia [65]. Chronic inflammation from the afore-
mentioned causes can activate the immune system causing
dysregulated NFκB activation (the master switch) resulting
in excessive and prolonged cytokine production, decreased
neurogenesis, increased oxidative stress and apoptosis and
glutamatergic activation bringing about structural abnorm-
alities as well as alterations in brain rewiring. CNVs, such
as those present in the chromosome 16p13.11 micro-
duplication, for example increased NDE1 expression, may
increase risk by changing the expression of dosage-sensitive
genes which themselves are either activators of or are
regulated by an NFκB pathway gone awry. The specific
validation and mechanistic challenge of these genes within
the 16p13.11 microduplication, both individually and in
combination gene sets, is an imposing yet potentially
rewarding investigation for the future to dissect the precise
mechanism linking the NFκB signaling pathway with neu-
ropsychiatric and neurodevelopmental disorders and may
drive the development of novel therapies [66].
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